Bioretec (BRETEC) Q3 2026 earnings summary

Executive summary

• Q3 net sales rose 85.5% YoY to EUR 1.328m; Jan–Sep sales increased 30.8% to EUR 3.648m, with Q3 growth across all regions.

• Jan–Sep adjusted sales margin improved to 69.0% from 57.5%, and net loss narrowed to EUR 6.517m from EUR 7.482m.

Financial highlights

• Q3 EBITDA was EUR -1.746m vs. EUR -1.768m; EBIT was EUR -1.806m vs. EUR -1.823m; net loss was EUR 1.839m vs. EUR 1.854m.

• Jan–Sep EBITDA was EUR -5.371m vs. EUR -6.325m; EBIT was EUR -5.552m vs. EUR -6.483m.

• Cash and cash equivalents were EUR 9.251m at period-end, vs. EUR 7.263m a year earlier and EUR 4.126m at year-end 2025.

• Jan–Sep undiluted EPS was EUR -0.008 vs. EUR -0.28; diluted EPS was EUR -0.004 vs. EUR -0.22.

Outlook and guidance

• 2026–2028 targets: net sales above EUR 10m by end-2028 and average sales margin above 70% during the strategy period; targets depend on capital infusions and exclude potential partnership-driven acceleration.

• Strategy targets at least one new product or indication every 12–18 months, expansion of the RemeOs portfolio, and stronger U.S. and OUS commercialization.

• Near-term focus is sustaining sales growth and improving margins; spending is expected to remain stable and disciplined while advancing the pipeline. Product commercialization timing depends on regulatory approvals and R&D resource prioritization.